Equities

Nektar Therapeutics

Nektar Therapeutics

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.26
  • Today's Change-0.015 / -1.18%
  • Shares traded742.24k
  • 1 Year change+76.76%
  • Beta0.5996
Data delayed at least 15 minutes, as of Sep 20 2024 20:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform0
Hold3
Sell1
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects the share price price of Nektar Therapeutics to remain relatively unchanged over the next year.
High2.4%1.30
Med2.4%1.30
Low2.4%1.30

Earnings history & estimates in USD

On Aug 08, 2024, Nektar Therapeutics reported 2nd quarter 2024 losses of -0.25 per share.
The next earnings announcement is expected on Nov 05, 2024.
Average growth rate+0.38%
Nektar Therapeutics reported annual 2023 losses of -1.45 per share on Mar 04, 2024.
Average growth rate+10.96%
More ▼

Revenue history & estimates in USD

Nektar Therapeutics had 2nd quarter 2024 revenues of 23.49m. This bettered the 17.55m consensus of the 5 analysts covering the company. This was 8.78% above the prior year's 2nd quarter results.
Average growth rate+3.96%
Nektar Therapeutics had revenues for the full year 2023 of 90.12m. This was 2.10% below the prior year's results.
Average growth rate-2.93%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.